Oct. 23 at 12:08 PM
$TNGX $TNGX data out. Secures private funding for phase 3
Tolerability looks BIC
Impressive RR in histology agnostic MTAP deleted tumors
Overall RR 27%. (
$BMY reported 21%. )
BMS drug had some dose limiting toxicities of seizure and GI. Which is not seen with tango. There was mild liver enzyme, elevation with BMY which could complicate combinations and this is not seeing with Tango drug
2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% –
– Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 –
– 49% ORR and mPFS 9.1 months in histology agnostic cohort of multiple late line, difficult to treat cancers provide further evidence of strong activity –